Base
N2660812015-07-14New YorkClassification

The tariff classification of Pyridostigmine Bromide Tablets in dosage form, from India

U.S. Customs and Border Protection · CROSS Database · 1 HTS code referenced

Summary

The tariff classification of Pyridostigmine Bromide Tablets in dosage form, from India

Ruling Text

N266081 July 14, 2015 CLA-2-30:OT:RR:NC:2:238 CATEGORY: Classification TARIFF NO.: 3004.90.9140 Mr. Pradeep Shah Zydus Pharmaceuticals (USA) Inc. 73 Route 31 North Pennington, NJ 08534 RE: The tariff classification of Pyridostigmine Bromide Tablets in dosage form, from India Dear Mr. Shah: In your letter dated June 19, 2015, you requested a tariff classification ruling. The subject product, Pyridostigmine Bromide Tablets (60 mg) is a medicinal preparation containing Pyridostigmine Bromide, a cholinesterase inhibitor, as the active ingredient. It is indicated for the treatment of muscle weakness in patients with myasthenia gravis. The applicable subheading for the Pyridostigmine Bromide Tablets in dosage form will be 3004.90.9140, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the central nervous system: Other.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at judy.h.lee@cbp.dhs.gov. Sincerely, Gwenn Klein Kirschner Director National Commodity Specialist Division